RENO, Nev., Sept. 4, 2012 /PRNewswire/ -- Lifeline
Biotechnologies, Inc. (OTC Market: LLBO) announces the award
of US Patent #8,226,572 B2 for Methods for Collecting and
Analyzing Thermal Data Based on Breast Surface Temperature to
Determine Suspect Conditions.
"This Methods patent adds to our core intellectual property
along with the device patent we received this past May and for our
previously FDA approved 510(k) medical device" says Jim Holmes, Chairman/CEO. "Our basis
for originally applying for the three software patents was as a
result of the software technical work completed by world renowned
pattern recognition specialists we engaged at Nanyang Technological University, Singapore.
Once they had modified and improved our technology capabilities to
achieve acceptable and competitive accuracy, sensitivity (false
positive) and specificity (false negative) utilizing our patient
data, we were convinced our processes were patentable. This
novel and exciting technology holds the potential to change the way
early breast tissue abnormalities and breast cancers are detected"
concluded Holmes.
First Warning Systems, Lifeline Biotechnologies' exclusive
licensee, is currently updating the patient data collection device
and its interpretive software to complete the product package in
preparation for market entry. First Warning is conducting a
funding round. See firstwarningsystems.com/investors.html for
more information.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS' principal
shareholder is Lifeline Biotechnologies, Inc. Lifeline has
licensed FWS with the worldwide exclusive right for
development, manufacturing, marketing and commercialization of its
intellectual property. The product is a device and
process that detects breast tissue abnormalities. Many of
these tissue abnormalities will develop into breast diseases, some
of which will be breast cancers. The FWS process does not
involve compression or radiation and is noninvasive. Three clinical
trials with over 650 participants have achieved proof of concept
and superior outcomes when compared to other protocols. FWS
is planning a final, limited clinical trial and a 510k device
classification to validate the fourth generation of the FWS
product. FWS is preparing to apply for a Euro CE Mark to market in
the UK, EU and Russian markets. See FWS' video, "Breast Cancer
Tumor Progression" at www.firstwarningsystems.com/investors.html
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in
1994 is based in Reno, NV.
LLBO has invested over $10M in a
device and process for early detection of breast tissue
abnormalities some of which are cancerous or pre-cancer.
Three "Proof of Concept" clinical trials of over 650 women have
been completed and three patents (one hardware, two software) have
been awarded. www.lbti.com.
Lifeline's efforts continue to have DTC remove the chill and
allow trading to resume.
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
For more information, contact: Jim Holmes, CEO
775-852-3222 Email: Jholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.